Stephen Saad's Wealth Takes A Hit As Aspen Pharmacare Stock Plunges, Erasing 41 Million

Aspen Pharmacares stock slid 7.27 in 55 days, wiping R750.75 million 41.15 million from CEO Stephen Saads stake.

Aspens first-half revenue rose 3.87 to 1.2 billion, while profit climbed 3.2 to nearly 130 million, despite market challenges.

Shares fell from R180.56 to R167.44, pushing Aspens market cap down to 4 billion, impacting major shareholders like Saad.

South African pharma tycoon Stephen Saad, CEO of Aspen Pharmacare, has seen his wealth take a hit as the value of his stake in Africas largest drugmaker drops. The decline comes as Aspens share price continues to slide on the Johannesburg Stock Exchange JSE .

Saad, who owns a 12.8-percent stake in the companyamounting to 57,221,750 sharesremains one of South Africas richest businessmen and a key player on the JSE. However, in the past 55 days, his stake has lost R750.75 million 41.15 million as investors pull back from Aspen. This downturn follows a 44 million gain in January , which had lifted his stake to R10.26 billion 550.1 million.

Aspen Pharmacare , founded by Stephen Saad in 1997, has grown into a major force in South Africas pharmaceutical industry, playing a key role in his wealth. With operations in more than 115 countries, the company has expanded steadily under his leadership.

In the first half of its 2025 fiscal year , Aspen reported solid financial results, with revenue climbing 3.87 percent to over 1.2 billion and profit rising 3.2 percent to nearly 130 million. The strong performance was driven by steady growth across all business segments, especially in commercial pharmaceuticals.

Despite this positive performance, Aspens stock has struggled. Over the past 55 days, its shares on the JSE have dropped 7.27 percent, slipping from R180.56 9.9 on Jan. 31 to R167.44 9.18. This decline has pulled the companys market value down to around 4 billion, resulting in steep losses for shareholders.